cbdMD Acquires Twinlab for $4M, Targets 40% Revenue Growth and Portfolio Diversification
cbdMD's acquisition of Twinlab for $4 million strategically diversifies its product portfolio beyond hemp-derived offerings, aiming for a 40% annual revenue increase by leveraging Twinlab's established brand and retail distribution.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
cbdMD's recent acquisition of legacy supplement brand Twinlab for approximately $4 million signals a strategic pivot towards portfolio diversification amid persistent regulatory uncertainty surrounding hemp-derived products. This move aims to mitigate risk by expanding into established wellness, weight management, and longevity categories, leveraging Twinlab's recognised brand equity and extensive distribution networks built over decades.
The integration is projected to boost the combined entity's annual revenue by 40%, indicating a strong belief in the synergistic potential of combining cbdMD's innovation-driven growth with Twinlab's market penetration. Twinlab, a brand with significant heritage despite past financial difficulties, including a bankruptcy in the early 2000s, offers immediate access to a broader consumer base and retail shelf space. Maintaining Twinlab’s current CEO suggests an intention to preserve operational continuity and brand identity while integrating the two businesses.
This acquisition highlights a growing trend within the supplement industry: companies heavily invested in niche or novel ingredient categories are seeking stability and broader market appeal through M&A activities. For manufacturers, this implies a potential shift in production volumes and raw material demands as newly merged entities rationalise their supply chains and product lines. For brand owners, it underscores the value of established brand recognition and robust distribution, even for heritage brands that have navigated challenging market cycles.
What this means for United States
US brand owners and manufacturers should anticipate increased competitive pressure from diversified portfolios combining hemp and traditional supplement lines. This acquisition exemplifies a strategy to navigate FDA ambiguity on CBD by investing in established, compliant product categories. Manufacturers may see shifts in demand profiles, favouring production lines capable of handling both novel and conventional ingredients efficiently. Procurement teams should monitor material demands for wellness, weight management, and longevity segments as consolidated entities optimise their supply chains. The $4 million valuation for a legacy brand like Twinlab also sets a benchmark for potential M&A activities involving other established, but potentially underperforming, brands in the US market.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.